Join us in Scottsdale, AZ, for a dynamic forum bringing together top experts from across the state to discuss advancements in oncology care, the intricacies of new and existing treatments, and the influence of national policies on state-level initiatives. Reserve your complimentary spot now!
PROVIDER REGISTRATION

Provider Registration - inclusive of licensed physicians and allied health professionals including but not limited to registered nurses, nurse practitioners, clinical nurse specialists, pharmacists, physician assistants, administrators, social workers, and office managers in an oncology practice or university; Fellows; Retirees. Provider registrants must not be employed by an Industry company (see below).

For assistance with provider registration, please email Lu Anne Bankert, Leadership Relations Manager, at lbankert@accc-cancer.org.

Exhibitor Information

Industry Registration – open only to confirmed exhibitors. A registration link will be sent via email approximately 7-8 weeks prior to the event. Any Industry attendees that register as a Provider will be voided. Please email corporaterelations@accc-cancer.org with any questions.

• Industry Registration is inclusive of anyone working for Pharmaceutical, Business Tools/Technology, Diagnostics/Testing and Consulting companies.

For questions about the meeting, please email the Meetings Department.

Venue & Travel Information

DoubleTree Resort by Hilton Hotel Paradise Valley - Scottsdale
5401 N Scottsdale Rd
Scottsdale, AZ 85250
(480) 947-5400

This conference will not be holding a room block. To make a reservation please contact the hotel.

Hotel Parking:
Complimentary valet parking.

CME/CNE

This educational activity will be awarding continuing education credits.

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice?

This live, virtual symposium will bring together a world-renowned expert in the management of melanoma with a local community oncologist to discuss the integration of tumor-infiltrating lymphocyte (TIL) therapy into the care of patients with advanced melanoma.
Learn More